Critical Illness, ICU Acquired Weakness, Sarcopenia
Conditions
Keywords
ICU Acquired Weakness, Critical Care, Long Term Acute Care Hospital, Protein, Neuromuscular electric stimulation, Physical Rehabilitation, Geriatric population
Brief summary
Older ICU survivors with ICU acquired weakness (ICUAW) are malnourished, sarcopenic, and functionally debilitated as a consequence of the high burden of comorbidities common in the elderly. To address the sequalae of critical illnesses, the investigators will perform a trial incorporating an intervention that combines mobility-based physical rehabilitation (MRP), high protein supplementation (HPRO), and neuromuscular electric stimulation (NMES). The investigators will then assess both clinical and functional outcomes and determine the relationship of disability with systemic inflammation.
Detailed description
Annually, nearly 3 million patients ≥ 65 years old are admitted to intensive care units (ICUs) nationwide, 20% of whom experience a long, protracted ICU stay resulting in muscle deconditioning, atrophy, inflammation, and functional disability necessitating transfer from the ICU to a long term acute care hospitals (LTACH). In the LTACH exacerbations of chronic comorbidities and the cycle of prolonged bed rest, ongoing inflammation and malnutrition often leads to continued functional disability, immobility, prolonged mechanical ventilation and increased one-year mortality of up to 25%. After a patient has survived critical illness and is transferred to an LTACH facility, one of the major challenges of their continued care is how to address - and ameliorate - their profound physical and functional deficits. To address these sequalae of chronic critical illness, the investigators will perform a trial incorporating an intervention that combines mobility-based physical rehabilitation (MRP), high protein supplementation (HPRO) and neuromuscular electric stimulation (NMES) to assess both clinical and functional outcomes and to determine the relationship of disability with systemic inflammation. The investigators will prospectively randomize patient to receive our multicomponent intervention or usual care and assess the outcomes of functional mobility, change in muscle mass and discharge disposition. Additionally, the investigators will determine the effects of our intervention on inflammatory cytokine profiles to determine to what degree systemic inflammation mediates clinical recovery.
Interventions
COMBINATION_PRODUCTMRP and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)
Mobility-based physical rehabilitation sessions performed 5 times/week by a study PT to provide strength and cardiopulmonary endurance training. High whey protein shakes prescribed to a total intake of 1.6-1.8 g/kg/d in 2 divided doses based on caloric needs. 2 x 30-minute lower extremity electric stimulation sessions/day, 5 times/wk performed by study PT.
Sponsors
University of Maryland, Baltimore
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
60 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. LTACH admission within 72 hours 2. Age ≥ 60 years old 3. Prior ICU stay ≥ 2 weeks 4. Able to follow commands in English 5. Pre-ICU Barthel Index ≥ 70 6. Able to give consent 7. Able to perform physical therapy 8. All four limbs intact and mobile prior to LTACH admission
Exclusion criteria
1. Acute kidney injury with a glomerular filtration rate \<15 ml/min 2. Diagnosis of severe organ dysfunction including end stage liver disease or cirrhosis 3. Diagnosis of active cancer 4. Severe functional impairment or physical impairment to rehabilitation 5. Liver function tests \>2.5x normal limits 6. Chronic dementia or cognitive impairment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Muscle mass | Days 0 to 14 to 28 | Muscle mass will be measured by lower extremity muscle CT scans to calculate muscle volume and cross sectional area. |
| Change in Muscle strength | Days 0, 7, 14, 21 and 28 | Handgrip strength obtained using a hand grip dynamometer and manual muscle testing using hand held dynamometer |
| Change in Systemic Inflammation | Days 0, 7, 14, 21 and 28 | Quantitative analysis of CRP, IFN-γ, IL-1α, IL-1β, IL-6, and IL-8. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Functional status - SPPB | Days 0, 7, 14, 21 and 28 | Functional status will be assessed by using the Short Physical Performance Battery (SPPB) |
| Change in Functional status - FSS-ICU | Days 0, 7, 14, 21 and 28 | Functional status will be assessed by using the Functional Status Score in the ICU (FSS-ICU). |
| Change in Mobility status - ICU mobility Scale | Days 0, 7, 14, 21 and 28 | Mobility status will be assessed weekly using the 1-item ICU Mobility Scale weekly in those physically capable. |
| Change in Mobility status - 6 minute walk distance | Days 0, 7, 14, 21 and 28 | Mobility status will be assessed weekly using the total 6 Minute Walk distance in those physically capable. |
| Change in Mobility status - gait speed | Days 0, 7, 14, 21 and 28 | Mobility status will be assessed weekly using gait speed in those physically capable. |
| Discharge disposition (LTACH to home, nursing home, acute rehabilitation, readmission, or death) | up to or after Day 28 | Discharge disposition from the LTACH to home, nursing home, acute rehabilitation, readmission, or death) |
Countries
United States
Contacts
CONTACTAvelino C Verceles, M.D., M.S.
Outcome results
None listed